ASH 2018 | Nivolumab with ibrutinib for Richter’s transformation

Nitin Jain

Outcomes for chronic lymphocytic leukemia (CLL) patients with Richter’s transformation (RT) are poor, with a median survival of less than 1 year with chemoimmunotherapy. Here, Nitin Jain, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the Phase II clinical trial investigating the combination of nivolumab, an anti-PD1 monoclonal antibody, with ibrutinib in patients with relapsed/refractory CLL or RT (NCT02420912). Dr Jain discusses the safety and efficacy data, revealing the combination of nivolumab and ibrutinib to have clinical activity. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
Share this video